RESEARCH TRIANGLE PARK, N.C., July 21 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that it has expanded its clinical management team with the appointment of Timothy King, MSPH, as Vice President of Clinical Operations and Herve Mommeja-Marin, MD, as Vice President of Clinical Research.
In these new roles, Mr. King will oversee clinical operations and site management for Chimerix and Dr. Mommeja-Marin will oversee clinical strategy and study design. Both individuals will report to Wendy Painter, MD, Chief Medical Officer.
"Tim King and Herve Mommeja-Marin bring to Chimerix a wealth of talent and knowledge within infectious diseases which will be of great value as we advance of our antiviral clinical development programs," said Kenneth I. Moch, President and CEO. "We anticipate significant progress in our two clinical stage programs - CMX001 against double-stranded DNA viruses and CMX157 against HIV - and look forward to working with Tim and Herve as we develop these assets."
Mr. King has over 20 years of global experience managing and directing device and drug development clinical trials. Most recently he served as a Group Director at Quintiles, where he had responsibility for more than 20 Phase I to IV trials in over 40 countries for a wide range of drugs, biologics, devices and diagnostics. Mr. King's prior experience includes serving as the Head of Clinical Operations for Infectious Diseases, Hepatology, Vaccines, and Transplants at Duke Clinical Research Institute, where he oversaw programs in cytomegalovirus, hepatitis, and HIV. Mr. King holds a masters degree in epidemiology from the University of North Carolina.
Dr. Mommeja-Marin brings to Chimerix over 20 years of global medical and clinical research experience in infectious and respiratory disease and clinical medicine. Most recently he was Senior Medical Director, Infectious Diseases, for i3 Research, a contract research organization, where he was the lead therapeutic expert in infectious diseases. His background includes numerous Phase I through Phase IV clinical trials, including more than 25 late-stage trials. Previously, Dr. Mommeja-Marin was Director of Clinical Research for Gilead Sciences, Inc., where he was responsible for the global development of hepatitis B and hepatitis C programs. He also held the positions of Clinical Research Physician at Triangle Pharmaceuticals and Physician of Internal Medicine and Infectious Diseases at Assistance Publique- Hopitaux de Paris in France. Dr. Mommeja-Marin received a medical degree from Paris VII University, France. He is certified in internal medicine and multiple subspecialties.
Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies. CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on the company's extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs. Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix.com.
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved